Clinical Trials Browser

Completed × Hodgkin Disease × Nivolumab × Clear all

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Hodgkin Disease

NCT03436862 2023-12-05

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Phase 2 Completed

37 enrolled 6 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Hematologic Neoplasms

NCT02181738 2023-11-28

CheckMate 205

Phase 2 Completed

294 enrolled 32 charts

Hodgkin Disease

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Phase 1/2 Completed

140 enrolled 23 charts

CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT04091490 2023-09-21

Nivo-DHAP

Phase 2 Completed

Hodgkin Disease

NCT02572167 2022-11-08

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

93 enrolled 13 charts

Hodgkin Disease

NCT02973113 2021-07-21

PREVALE

Phase 1 Completed

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03343652 2020-05-28

NB001

Phase 1/2 Completed

Hodgkin Disease